KNSA // Kiniksa Pharmaceuticals International plc (Class A)
FA <GO> NASDAQ RQD COCKPIT → CIK 0001730430 ↗ Health Care • Biotechnology: Pharmaceutical Preparations
$90.80 ▼ -1.44
(-1.56%)
MKT CAP: $7.25B • VOL: 999.0K
52W L $37 52W H $98
KNSA // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $677.6M | $423.2M | $270.3M |
| YoY Revenue Growth % | +60.1% | +56.6% | — |
| Gross Profit | $599.9M | $362.3M | — |
| Gross Margin % | 88.5% | 85.6% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $77.2M | -$45.6M | -$25.2M |
| Operating Margin % | 11.4% | -10.8% | -9.3% |
| Net Income (GAAP) | $59.0M | -$43.2M | $14.1M |
| EBITDA (Normalized) | $78.5M | -$45.4M | -$15.5M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $138.0M | $25.7M | $13.3M |
| Capital Expenditures (CapEx) | $1.6M | $277.0K | $12.2M |
| Free Cash Flow (FCF) | $136.4M | $25.4M | $1.1M |
| FCF Margin % | 20.1% | 6.0% | 0.4% |
| Return on Invested Capital (ROIC %) | 12.4% | -11.3% | -0.8% |
| Cash & Short-Term Equivalents | $165.6M | $183.6M | — |
| Total Debt (Short + Long Term) | $88.2M | $64.0M | $986.5M |
| Total Stockholders' Equity | $567.6M | $438.4M | $2.02B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR KNSA.